Exosomes as Biomimetic Nanoplatforms for Synergistic Targeted Chemotherapy and Photothermal Treatment of Breast Cancer
Journal of Biochemical and Molecular Toxicology · 2026-06 · 40 (6)
DOI: 10.1002/jbt.70971 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Biochemical and Molecular Toxicology, online erschienen am 15.06.2026. Verfasst von Harsha Sanil und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, University of Kerala, Thiruvananthapuram, Kerala, India. Hauptthemen laut MEDLINE: Exosomes, Biomimetic Materials, Photothermal Therapy, Antineoplastic Agents. Die Arbeit nennt 111 Literaturangaben. Gefördert von: Start-up Research Grant from Science and Engineering Research Board (SERB), Start-up grant for new faculty from University Grants Commission (UGC) India, University of Kerala research support in the form of Plan and Nonplan Funds.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Breast cancer remains the most common cancer in women worldwide, with approximately 2.3 million new cases and 685,000 deaths annually (WHO, 2024). Triple‐negative breast cancer (TNBC), the most aggressive subtype, has < 15% 5‐year survival in metastatic cases, while conventional therapies are hampered by off‐target toxicity, multidrug resistance, and poor tumor accumulation (< 0.7% injected dose per gram of tumor (ID/g)). We present engineered exosomes as next‐generation Trojan horses for TNBC: NIR‐activatable photothermal agents (polydopamine, BPQDs, or ICG) are integrated into the membrane and chemotherapeutics or nucleic acids (doxorubicin, paclitaxel, siKRAS, siPD‐L1, miR‐145) encapsulated in the lumen. This “smart” platform exploits exosomes’ natural tumor‐homing and immune‐evasive properties; a single low‐power 808 nm laser pulse triggers mild hyperthermia (42°C–45°C), immunogenic cell death, and burst payload release, converting “cold” TNBC into “hot” tumors. In orthotopic and metastatic 4T1/MDA‐MB‐231 models, one intravenous dose plus 5‐min irradiation achieved a substantial tumor reduction in preclinical models, significant metastasis inhibition in murine models, long‐term memory immunity, and 15%–18% IDg tumor accumulation with negligible toxicity. Major challenges—donor heterogeneity, low yields, rapid clearance, regulatory gaps, and limited NIR‐II probes—are being overcome via single‐cell omics, advanced bioreactors, CD47/PEGylation engineering, rigorous CMC standards, and PbS quantum dot loading. Future directions include AI/CRISPR‐optimized design, NIR‐II platforms, checkpoint inhibitor synergy, with early‐stage clinical translation of photothermal and immunomodulatory exosome‐based therapeutics currently underway, highlighting their potential to advance precision oncology. “However, challenges including scalability, batch variability, and regulatory standardization remain significant barriers to clinical translation.”
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, University of Kerala, Thiruvananthapuram, Kerala, India.
- Department of Biochemistry, Centre for Advanced Cancer Research, University of Kerala, Thiruvananthapuram, Kerala, India.
- CEPCI Laboratory & Research Institute (The Cashew Export Promotion Council of India), Kerala, India.
- Department of Nanoscience and Nanotechnology, University of Kerala, Thiruvananthapuram, Kerala, India.
- Department of Biotechnology, University of Kerala, Thiruvananthapuram, Kerala, India.
- Department of Biochemistry, Government Arts and Science College, Kulathoor, Neyyattinkara, Thiruvananthapuram, India.
ORCID-Profile: Muthunayagam Vibin, Janeesh Plakkal Ayyappan
Förderung
- Start-up Research Grant from Science and Engineering Research Board (SERB)
- Start-up grant for new faculty from University Grants Commission (UGC) India
- University of Kerala research support in the form of Plan and Nonplan Funds
- Kerala Biotechnology Commission, Kerala State Council
Zitieren
APA
Sanil, H., Revathi, V., Sudhina, S., Yesudas, C., Nazarudeen, A., Aswathy, U. V., Abhirami, N., Chandran, A., Athul, P. S., Siril, D. M., Yesudas, C., Radhika, A., Vibin, M., & Ayyappan, J. P. (2026). Exosomes as Biomimetic Nanoplatforms for Synergistic Targeted Chemotherapy and Photothermal Treatment of Breast Cancer. Journal of Biochemical and Molecular Toxicology, 40(6). https://doi.org/10.1002/jbt.70971
Vancouver
Sanil H, Revathi V, Sudhina S, Yesudas C, Nazarudeen A, Aswathy UV, et al. Exosomes as Biomimetic Nanoplatforms for Synergistic Targeted Chemotherapy and Photothermal Treatment of Breast Cancer. Journal of Biochemical and Molecular Toxicology. 2026;40(6). doi:10.1002/jbt.70971
BibTeX
@article{Sanil2026,
author = {Sanil, Harsha and Revathi, Valliyodu and Sudhina, Sufina and Yesudas, Chandana and Nazarudeen, Areej and Aswathy, Usha Vijayamoorthy and Abhirami, Nalinakshan and Chandran, Akash and Athul, Prasannakumar Sreeja and Siril, Diya Maria and Yesudas, Chaithanya and Radhika, A and Vibin, Muthunayagam and Ayyappan, Janeesh Plakkal},
title = {Exosomes as Biomimetic Nanoplatforms for Synergistic Targeted Chemotherapy and Photothermal Treatment of Breast Cancer},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2026},
volume = {40},
number = {6},
doi = {10.1002/jbt.70971}
}
EUVIMED